Company Website

Contact Information:
Valerie Atohi
vatohi@sklsi.com
352-359-7596

Patrick Waldron
pwaldron@sklsi.com
407-866-3750

Virtual Exhibit Hall Home

SK life science is a subsidiary of SK biopharmaceuticals, focused on developing innovative, next-generation drugs. We have 27 years of experience in R&D and are dedicated to changing the status quo in CNS. We currently have 8 compounds in the clinical development pipeline.

XCOPRI (cenobamate) is a new option to treat adults with partial-onset seizures, which is an often difficult-to-control condition. The safety and efficacy of XCOPRI was established in two randomized, double-blind, placebo-controlled studies that enrolled 655 adults. In these studies, patients had partial-onset seizures with or without secondary generalization for an average of approximately 24 years and median seizure frequency of 8.5 seizures per 28 days during an 8-week baseline period. During the trials, XCOPRI reduced the percent of seizures per 28 days compared with the placebo group.

XCOPRI Seizure Reduction Information

XCOPRI Dosing Information

XCOPRI Full Prescribing Information